RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer
September 19, 2024 - At the Cantor Fiztgerald Global Healthcare Conference fireside chat today, ONCY's Kirk Look stated that the company only targeted & modeled the market size for pelareorep + paclitaxel treatment in the United States - with 55,000 HR+/HER2- patients in the US as the patient population target for pelareorep.
The 55,000 HR+/HER2- patients modeled for 3rd line pelareorep treatment in the United States would have been based on approximately 310,720 women and 2,800 men being diagnosed with invasive breast cancer in the United States in 2024, with aproximately 203,000 presenting with HR+/HER2- mBC.
In 2022, approximately 604,900 women were diagnosed with breast cancer in the WHO Europe region. Incidence in the EU-27 in 2022 was estimated to be 375,000
Therefore approximately 243,000 mBC patients would be diagnosed with HR+/HER2- in the EU-27, for example. Of this conservative number, approximately 67,000 would be further modeled for pelareorep + paclitaxel therapy in addition to the 55,000 HR+/HER2- mBC patients modeled in the United States.
Consequently around 122,000 pelareorep eligible HR+/HER2- mBC patients is the cumulative number that could be more appropriately modeled for the pelareorep in mBC target in the combined United States and EU-27 global regions. Using ONCY's conservative modeling equations, peak pelareorep annual sales would reach approximately US$5.8 Billion in HR+/HER2- mBC alone.